PSPeter F. Schnatz

Peter F. Schnatz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter F. Schnatz has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Race, Ethnicity, and Mortality Following Major Osteoporotic Fracture: Results from the Women’s Health Initiative Study

    by Michaela Juels, Joseph C. Larson, Kristine E. Ensrud, Marcia L. Stefanick, Aladdin H. Shadyab, Lorena Garcia, Rami Nassir, Peter F. Schnatz, Rebecca Nelson, Carolyn J. Crandall

    Background: Major osteoporotic fracture (MOF) is associated with increased mortality; however, few studies in postmenopausal women have examined racial and ethnic differences in 1-year and 5-year mortality following MOF. Objective: To assess 1-year and 5-year mortality following MOF by race and ethnicity. Design: This prospective cohort study included postmenopausal women enrolled in the Women’s Health Initiative (WHI), a population-based, multisite US study. Participants were followed from September 1994 to February 2023. Data were analyzed between August 2023 and November 2023. Participants: Postmenopausal women aged 50 to 79 years old who experienced a MOF (N = 32,675 in 1 year and 29,506 in 5 years following MOF). Main Measures: Self-reported race and ethnicity. All-cause mortality was determined by death certificates, reports of surrogates, and the National Death Index Search. Key Results: The baseline mean age of participants was 77.0 [SD = 8.5] years with 31,223 [95.6%] White participants in the 1-year mortality analysis, and 76.3 [SD = 8.5] years with 28,212 [95.6%] White participants in the 5-year mortality analysis. In fully adjusted models, compared to White women, Black women had a higher risk of mortality (adjusted odds ratio (aOR) = 1.42, 95% CI [1.06, 1.90], while Asian women had a lower risk of mortality (aOR = 0.48 95% CI [0.27, 0.88]), within 1 year following MOF. Compared to White women, the mortality risk within 5 years after MOF was significantly higher among American Indian/Alaska Native (aOR = 3.30, 95% CI [1.65, 6.60]) and lower among Asian (aOR = 0.58, 95% CI [0.42,0.80]) women. While there were no mortality differences by ethnicity 1 year following MOF, Hispanic/Latina women were less likely to die 5 years following MOF (aOR = 0.74, [95% CI 0.57–0.96]) compared to Non-Hispanic/Latina women. Conclusions: In this large prospective study, mortality following MOF differed by race. Future research is needed to delineate the mechanism behind these associations.


  • DXA-derived abdominal fat-free mass to predict MRI skeletal muscle mass in postmenopausal women

    by E. Walker, A.M. Chalke, V.L. Bland, K.E. Lind, Z. Chen, R.M. Blew, A.O. Odegaard, C.A. Thomson, B. Caan, J.S. Nicholas, et al.

    Dual-energy X-ray absorptiometry (DXA) is more available than gold-standard magnetic resonance imaging (MRI), but DXA ability to estimate abdominal skeletal muscle mass (SMM) is unknown. DXA-derived abdominal fat-free mass (FFM; Hologic QDR2000 or QDR4500w) was correlated with single-slice MRI SMM at L4 ( N = 69; r QDR2000 = 0.71, QDR4500w = 0.69; p < 0.0001). Linear regression to predict SMM, including DXA FFM, BMI, and age, resulted in an R-squared of 0.72 and 0.65 for QDR2000 and QDR4500. Bland-Altman limits of agreement were ±21 and ±31 g for 2–3 standard deviations from the mean difference. DXA predicted abdominal SSM is a moderate proxy for MRI abdominal SMM.

  • Association of Diet Quality With Risk of Incident Rheumatoid Arthritis in the Women’s Health Initiative

    by Kanika Malani, Sushaili Pradhan, Mir Moafi Madani, Mary B. Roberts, Aladdin Shadyab, Matthew Allison, Theodore M. Brasky, Peter F. Schnatz, Linda Snetselaar, Charles B. Eaton


  • The association between incidentally found breast arterial calcification on routine screening mammography and the development of coronary artery disease and stroke: results of a 10-year prospective study

    by Matthew Nudy, Ragad Asmaro, Xuezhi MD Jiang, Peter F. Do Schnatz

    Objective: The objective of this study is to assess whether the presence of breast arterial calcifications (BACs) found on routine mammography is prospectively associated with the development of cardiovascular disease (CVD) events after 10 years of follow-up. Methods: Women presenting for screening mammography were enrolled in this prospective cohort. Baseline data were collected including history of CVD and CVD risk factors. Mammograms were assessed for the presence or absence of BAC. Participants completed questionnaires 10 years after baseline that assessed the development of CVD (coronary artery disease [CAD] and stroke) and CVD risk factors. Results: Of the 1,995 participants who enrolled at baseline, complete 10-year follow-up data were available for 1,039; of those, 114 (11.0%) were BAC-positive and 925 (89.0%) were BAC-negative at baseline. After controlling for age, BAC-positive women were more likely to develop CAD (odds ratio, 3.14; 95% confidence interval, 1.86-5.27; P < 0.001) compared with BAC-negative women after 10 years of follow-up. After controlling for age, BAC-positive women were more likely to have had a stroke (odds ratio, 5.10; 95% CI, 1.82-14.30) compared with BAC-negative women after 10 years. Conclusions: The presence of BAC on routine screening mammography was associated with a significantly increased risk of developing CAD and stroke after 10 years of follow-up. Additional large prospective, population-based studies are needed to confirm BAC as a predictor of future CVD events and its utility in stratifying a woman's risk of CVD.


  • The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials

    by Xuezhi MD Jiang, Aaron K. Aragaki, Matthew Nudy, JoAnn E. MD Manson, Aladdin H. Shadyab, Robert A. Wild, Carolina Valdiviezo, Margery Gass, Lisa Warsinger Martin, Kathy Pan, et al.

    Objective: The objective of this study was to assess the effect of menopausal hormone therapy (HT) on blood pressure control in postmenopausal women with hypertension. Methods: The Women's Health Initiative HT clinical trials were double-blinded, randomized, placebo-controlled studies of women aged 50 to 79 years testing the effects of HT (conjugated equine estrogens [CEE, 0.625 mg/d] or CEE + medroxyprogesterone acetate [MPA; 2.5 mg/d]) on risks for coronary heart disease and invasive breast cancer, the primary outcomes for efficacy and safety, respectively. This secondary analysis of the Women's Health Initiative HT trials examined a subsample of 9,332 women with hypertension (reported ever taking pills to treat hypertension or were taking antihypertensive medication) at baseline. Blood pressure was measured at baseline and up to 10 annual follow-up visits during the planned study phase. Antihypertensive medications were inventoried at baseline and years 1, 3, 6, and 9 during the study, and self-reported during extended follow-up: 2009-2010 and 2012-2013, which occurred median of 13 and 16 years after randomization, respectively. The intervention effect was estimated through year 6. Cumulative follow-up included all visits. Results: Compared with placebo, CEE-alone had significantly (P = 0.02) higher systolic blood pressure (SBP) by mean (95% confidene interval [CI]) = 0.9 (0.2-1.5) mm Hg during the intervention phase. For cumulative follow-up, the CEE arm was associated with increased SBP by mean (95% CI) = 0.8 (0.1-1.4) mm Hg (P = 0.02). Furthermore, CEE + MPA relative to placebo was associated with increased SBP by mean (95% CI) = 1.8 (1.2-2.5) mm Hg during the intervention phase (P < 0.001). For cumulative follow-up, the CEE + MPA arm was associated with increased SBP by mean (95% CI) = 1.6 (1.0-2.3) mm Hg (P < 0.001). The mean number of antihypertensive medications taken at each follow-up visit did not differ between randomization groups during the intervention or long-term extended follow-up of 16 years. Conclusion: There was a small but statistically significant increase in SBP in both CEE-alone and CEE + MPA arms compared with placebo during both the intervention and cumulative follow-up phases among postmenopausal women with hypertension at baseline. However, this increase in SBP was not associated with an increased antihypertensive medication use over time among women randomized to HT compared with placebo.


  • The severity of individual menopausal symptoms, cardiovascular disease, and all-cause mortality in the Women's Health Initiative Observational Cohort

    by Matthew Nudy, Aaron K. Aragaki, Xuezhi MD Jiang, JoAnn E. MD Manson, Matthew A. Allison, Aladdin H. Shadyab, Howard N. Hodis, Robert A. MD Wild, John A. Robbins, Simin MD Liu, et al.

    Objective: The aim of this study was to examine the association between common menopausal symptoms (MS) and long-term cardiovascular disease (CVD) and all-cause mortality. Methods: In an observational cohort of 80,278 postmenopausal women with no known CVD at baseline from the Women's Health Initiative, we assessed individual MS severity (mild vs none; moderate/severe vs none) for night sweats, hot flashes, waking up several times at night, joint pain or stiffness, headaches or migraines, vaginal or genital dryness, heart racing or skipping beats, breast tenderness, dizziness, tremors (shakes), feeling tired, forgetfulness, mood swings, restless or fidgety, and difficulty concentrating. Outcomes included total CVD events (primary) and all-cause mortality (secondary). Associations between specific MS, their severity, and outcomes were assessed during a median of 8.2 years of follow-up. All results were multivariable adjusted, and individual associations were Bonferroni corrected to adjust for multiple comparisons. A machine learning approach (least absolute shrinkage and selection operator) was used to select the most parsimonious set of MS most predictive of CVD and all-cause mortality. Results: The severity of night sweats, waking up several times at night, joint pain or stiffness, heart racing or skipping beats, dizziness, feeling tired, forgetfulness, mood swings, restless or fidgety, and difficulty concentrating were each significantly associated with total CVD. The largest hazard ratio (HR) for total CVD was found for moderate or severe heart racing or skipping beats (HR, 1.55; 95% confidence interval [CI], 1.29-1.86). The individual severities of heart racing or skipping beats, dizziness, tremors (shakes), feeling tired, forgetfulness, mood swings, restless or fidgety, and difficulty concentrating were associated with increased all-cause mortality. Moderate or severe dizziness had the largest HR (1.58; 95% CI, 1.24-2.01). Multiple symptom modeling via least absolute shrinkage and selection operator selected dizziness, heart racing, feeling tired, and joint pain as most predictive of CVD, whereas dizziness, tremors, and feeling tired were most predictive of all-cause mortality. Conclusion: Among postmenopausal women with no known CVD at baseline, the severity of specific individual MS was significantly associated with incident CVD and mortality. Consideration of severe MS may enhance sex-specific CVD risk predication in future cohorts, but caution should be applied as severe MS could also indicate other health conditions.


  • Association between coronary artery vitamin D receptor expression and select systemic risks factors for coronary artery atherosclerosis

    by M. Nudy, R. Xie, D. M. O’sUllivan, X. Jiang, S. Appt, T. C. Register, J. R. Kaplan, T. B. Clarkson, P. F. Schnatz

    The aim of this study is to analyze the association between coronary artery vitamin D receptor (VDR) expression and systemic coronary artery atherosclerosis (CAA) risk factors.Female cynomolgus mon... 目的:本研究的目的是分析冠状动脉维生素D受体(VDR)的表达与系统性冠状动脉粥样硬化(CAA)危险因素的关系。方法:雌性食蟹猴(n=39)每天摄入致动脉粥样硬化饮食, 包含相当于女性1000 IU/天的维生素D3。在这样摄入饮食32个月后, 每只猴子都经历了手术性绝经。绝经后32个月后, 对冠状动脉左前降支CAA和VDR的表达进行定量。测定血浆25OHD3、血脂及血清单核细胞趋化蛋白-1(M...


  • The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial

    by Matthew Nudy, Xuezhi Jiang, Aaron K. Aragaki, JoAnn E. MD Manson, Aladdin H. Shadyab, Andrew J. Foy, Jonathan Buerger, Anita M. Kelsey, Erin S. LeBlanc, Robert A. Wild, et al.

    Objective: This study evaluated whether vasomotor symptom (VMS) severity and number of moderate/severe menopausal symptoms (nMS) were associated with health outcomes, and whether calcium and vitamin D (CaD) modified the risks. Methods: The Women's Health Initiative CaD study was a double blind, randomized, placebo-controlled trial, which tested 400 IU of 25-hydroxyvitamin-D and 1,000 mg of calcium per day in women aged 50 to 79 years. This study included 20,050 women (median follow-up of 7 y). The outcomes included hip fracture, colorectal cancer, invasive breast cancer, all-cause mortality, coronary heart disease, stroke, cardiovascular death, and total cardiovascular disease (CVD). MS included: hot flashes, night sweats, dizziness, heart racing, tremors, feeling restless, feeling tired, difficulty concentrating, forgetfulness, mood swings, vaginal dryness, breast tenderness, migraine, and waking up several times at night. Associations between VMS severity and nMS with outcomes were tested. Results: No association between VMS severity and any outcome were found. In contrast, nMS was associated with higher stroke (hazard ratio [HR] 1.40 95% confidence interval [CI] 1.04-1.89 for ≥ 2 MS vs none; HR 1.20 95% CI 0.89-1.63 for 1 MS vs none, P trend = 0.03) and total CVD (HR 1.35, 95% CI, 1.18-1.54 for ≥ 2 MS vs none; HR 0.99, 95% CI, 0.87-1.14 for 1 MS vs none P trend < 0.001). CaD did not modify any association. Conclusion: Severity of VMS was not associated with any outcome. Having ≥2 moderate or severe MS was associated with an increased risk for CVD. The number of moderate/severe MS may be a marker for higher CVD risk. Video Summary: http://links.lww.com/MENO/A669.


  • Open Access

    25(OH)D 3 and Cardiovascular Risk Factors in Female Nonhuman Primates

    by Matthew J. Jorgensen, Lawrence L. Rudel, Matthew Nudy, Jay R. Kaplan, Thomas B. Clarkson, Nicholas M. Pajewski, Peter F. Schnatz

    To determine if interindividual differences in plasma concentrations of 25-hydroxyvitamin D(3) (25(OH)D(3)) have pathophysiologic significance, we evaluated a cohort of female monkeys, seeking to identify associations with clinically relevant cardiovascular risk factors, including age, abdominal obesity (waist circumference), and high-density lipoprotein cholesterol (HDL-C). One hundred fifty-five female vervet monkeys (Chlorocebus aethiops sabaeus) aged 3-25 years consumed a typical western diet for 7-8 weeks that provided a woman's equivalent of approximately 1000 IU/day of vitamin D(3). Measurements of vitamin D(3) and HDL-C concentrations, as well as waist circumference, were obtained. Among young monkeys (aged 3-5 years), compared to older monkeys (aged 16-25 years), the mean plasma 25(OH)D(3) concentrations were 82.3±3.2 ng/mL and 58.6±2.9 ng/mL (p<0.0001), respectively. Plasma 25(OH)D(3) concentrations had a range of 19.6-142.0 ng/mL (mean±standard error [SE] 66.4±1.7 ng/mL). 25(OH)D(3) concentrations were inversely associated with age (p<0.0001) and waist circumference (p=0.016) and were positively correlated with HDL-C (p=0.01). However, when statistically controlling for age, none of these relationships remained significant. Higher plasma concentrations of 25(OH)D(3) were associated with more favorable cardiovascular risk factors, with inverse associations observed between 25(OH)D(3) and abdominal obesity, HDL-C, and age. These associations were no longer significant when controlling for age.


  • Assessment of the Perceptions and Administration of the Human Papillomavirus Vaccine

    by Peter F. Schnatz, Kate Humphrey, David M. O'SUllivan

    To investigate practitioner acceptability of the recommendation to offer the human papillomavirus (HPV) vaccine to adolescent women. After obtaining institutional review board approval, 1,336 Connecticut-licensed pediatricians were contacted. A 16-question survey form was mailed, and responses received between January 20 and May 20, 2008, are reported. Of the 434 returned survey forms, 89 were not completed because the physicians were currently retired or practicing as subspecialists. Among the 345 valid survey forms, most pediatricians described their understanding about HPV as "moderately knowledgeable" (53.3%) or "very knowledgeable" (37.4%). There was a significant correlation between physician knowledge about HPV and willingness to discuss sexually transmitted infections (STIs; p < .001). Most pediatricians (91.0%) reported that they begin discussing STIs when their patients are between the ages of 10 and 16 years. More than 94% of pediatricians reported that they "always" or "sometimes" discuss the vaccine when discussing STIs. Pediatricians reported that 67% of patients agreed to receive the HPV vaccine. Reasons that 33% of parents choose not to have their children receive the vaccine include the unknown long-term effects (71.1%) and the belief that their child is not sexually active (66.4%). Primary adverse effects cited by pediatricians include injection site burning (77.4%), with fewer reports of fainting (15.1%), dizziness (13.6%), fever (9.3%), and nausea/vomiting (2.3%). Pediatricians in Connecticut who claim to be knowledgeable about HPV are more likely to initiate discussions of STIs. Addressing parental concerns and discussing the primary adverse effects may alleviate anxiety associated with HPV vaccination and increase vaccine administration.